Expand SYRE Menu
SYRE MENU

SYRE Latest Press Releases

-- February 6, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:01 PM

-- January 23, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:00 PM

-- January 12, 2026 --

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 Globe Newswire 8:00 AM

-- January 8, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:05 PM

-- December 5, 2025 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:05 PM

-- November 7, 2025 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:05 PM

-- November 4, 2025 --

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody Globe Newswire 4:01 PM

-- October 29, 2025 --

Spyre Therapeutics to Participate in Upcoming November Investor Conferences Globe Newswire 4:05 PM

-- October 24, 2025 --

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 Globe Newswire 8:00 AM

-- October 15, 2025 --

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million Globe Newswire 4:15 PM

-- October 13, 2025 --

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock Globe Newswire 9:07 PM
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants Globe Newswire 4:01 PM

-- October 5, 2025 --

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 Globe Newswire 9:00 AM

-- October 3, 2025 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:05 PM

-- September 15, 2025 --

Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes